PMID- 29414416
OWN - NLM
STAT- MEDLINE
DCOM- 20181231
LR  - 20181231
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 28
DP  - 2018 Apr
TI  - Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell 
      potential in the absence of glucose.
PG  - 33-38
LID - S1873-5061(18)30044-8 [pii]
LID - 10.1016/j.scr.2018.01.038 [doi]
AB  - The introduction of BCR/Abl tyrosine kinase inhibitors (TKI), such as 
      imatinib-mesylate (IM), has revolutioned the treatment of chronic myeloid 
      leukemia (CML). However, although extremely effective in inducing CML remission, 
      IM is unable to eliminate leukemia stem cells (LSC). This is largely due to the 
      suppression of BCR/Abl protein, driven by the reduction of energy supply due to 
      oxygen or glucose shortage, in stem cell niches of bone marrow. Here, we 
      investigated whether, in K562 and KCL22 CML cell cultures, glucose shortage 
      induces refractoriness of stem cell potential to IM. In the absence of glucose, 
      IM, while maintaining its detrimental effect on CML cell bulk, actually enhanced 
      colony formation ability and stem cell potential. This was paralleled by an 
      increased expression of the Nanog and Sox-2 stem cell markers. These evidences 
      stress further the importance of developing strategies alternative to TKI capable 
      to target LSC of CML.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Bono, Silvia
AU  - Bono S
AD  - Department of Experimental and Clinical Biomedical Sciences "Mario Serio", 
      Universita degli Studi di Firenze, Florence, Italy; Istituto Toscano Tumori, 
      Florence, Italy.
FAU - Dello Sbarba, Persio
AU  - Dello Sbarba P
AD  - Department of Experimental and Clinical Biomedical Sciences "Mario Serio", 
      Universita degli Studi di Firenze, Florence, Italy; Istituto Toscano Tumori, 
      Florence, Italy. Electronic address: persio@unifi.it.
FAU - Lulli, Matteo
AU  - Lulli M
AD  - Department of Experimental and Clinical Biomedical Sciences "Mario Serio", 
      Universita degli Studi di Firenze, Florence, Italy; Istituto Toscano Tumori, 
      Florence, Italy. Electronic address: matteo.lulli@unifi.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180131
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nanog Homeobox Protein)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Fusion Proteins, bcr-abl/metabolism
MH  - Glucose/*deficiency
MH  - Humans
MH  - Imatinib Mesylate/*pharmacology
MH  - K562 Cells
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*pathology
MH  - Nanog Homeobox Protein/metabolism
MH  - Neoplastic Stem Cells/drug effects/metabolism/*pathology
MH  - SOXB1 Transcription Factors/metabolism
MH  - Tumor Stem Cell Assay
OTO - NOTNLM
OT  - BCR/Abl protein expression
OT  - BCR/Abl signaling
OT  - Chronic myeloid leukemia
OT  - Glucose shortage
OT  - Imatinib treatment
OT  - Leukemia stem cell potential
EDAT- 2018/02/08 06:00
MHDA- 2019/01/01 06:00
CRDT- 2018/02/08 06:00
PHST- 2017/09/07 00:00 [received]
PHST- 2018/01/29 00:00 [revised]
PHST- 2018/01/29 00:00 [accepted]
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2019/01/01 06:00 [medline]
PHST- 2018/02/08 06:00 [entrez]
AID - S1873-5061(18)30044-8 [pii]
AID - 10.1016/j.scr.2018.01.038 [doi]
PST - ppublish
SO  - Stem Cell Res. 2018 Apr;28:33-38. doi: 10.1016/j.scr.2018.01.038. Epub 2018 Jan 
      31.